Acute treatment of migraines

CNS Drugs

Volumn 26, Issue 10, 2012, Pages 823-839

  Da Silva, Arnaldo N ^a   Tepper, Stewart J ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CLEVELAND CLINIC LERNER COLLEGE OF MEDICINE   (United States)

Author keywords

Dopamine receptor antagonists; Corticosteroids; Dihyrdroergotamine mesilate; Migraine; Migraine with aura; Migraine without aura; Nonsteroidal anti inflammatories; Opioid analgesics; Paracetamol; Tryptamines.

Indexed keywords

ACETYLSALICYLIC ACID; ALMOTRIPTAN; ANALGESIC AGENT; CHLORPROMAZINE; CODEINE; CORTICOSTEROID; DIAZEPAM; DICLOFENAC POTASSIUM; DIHYDROERGOTAMINE MESILATE; DOPAMINE RECEPTOR BLOCKING AGENT; ELETRIPTAN; ERGOTAMINE TARTRATE; FROVATRIPTAN; IBUPROFEN; KETOROLAC; MAGNESIUM; METOCLOPRAMIDE; NAPROXEN; NAPROXEN PLUS SUMATRIPTAN; NARATRIPTAN; NARCOTIC ANALGESIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PROCHLORPERAZINE; RIZATRIPTAN; SUMATRIPTAN; SUMATRIPTAN SUCCINATE; TRIPTAN DERIVATIVE; UNINDEXED DRUG; ZOLMITRIPTAN;

ABDOMINAL CRAMP; ABDOMINAL PAIN; AKATHISIA; ANALGESIA; ANALGESIC ACTIVITY; ARTICLE; BLURRED VISION; CHEST TIGHTNESS; CORTICOSTEROID THERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DROWSINESS; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; GALACTORRHEA; HEADACHE; HEART ARRHYTHMIA; HUMAN; INFERTILITY; INJECTION SITE FIBROSIS; LEG CRAMP; LEG PAIN; LIMB PAIN; LIVER FAILURE; LIVER TOXICITY; META ANALYSIS (TOPIC); MIGRAINE; MIGRAINE WITH AURA; MIGRAINE WITHOUT AURA; NAUSEA; NOSE DISEASE; NOSE STUFFINESS; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PATHOPHYSIOLOGY; PHOTOPHOBIA; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE DRUG DOSE; TABLET FORMULATION; TARDIVE DYSKINESIA; THORAX PAIN; TREATMENT PLANNING; TREMOR; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VASOCONSTRICTION; VISUAL ANALOG SCALE; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ANIMALS; HUMANS; MIGRAINE DISORDERS; VASOCONSTRICTOR AGENTS;

EID: 84865843170     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11635440-000000000-00000     Document Type: Article

References (96)

1. Leonardi M, Steiner TJ, Scher AT, et al. The global burden of migraine: measuring disability in headache disorders with WHO's Classification of Functioning, Disability and Health (ICF). J Headache Pain 2005 Dec; 6 (6): 429-40
2. Lipton RB, Stewart WF, Diamond S, et al. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache 2001 Jul-Aug; 41 (7): 646-57
3. Stewart WF, Ricci JA, Chee E, et al. Lost productive work time costs from health conditions in the United States: results from the American Productivity Audit. J Occup Environ Med 2003 Dec; 45 (12): 1234-46
4. Andlin-Sobocki P, Jonsson B, Wittchen HU, et al. Cost of disorders of the brain in Europe. Eur J Neurol 2005 Jun; 12 Suppl. 1: 1-27
5. Tepper SJ, Dahlof CG, Dowson A, et al. Prevalence and diagnosis of migraine in patients consulting their physician with a complaint of headache: data from the Landmark Study. Headache 2004 Oct; 44 (9): 856-64
6. Akerman S, Holland PR, Goadsby PJ. Diencephalic and brainstem mechanisms in migraine. Nat Rev Neurosci 2011 Sep 20; 12 (10): 570-84
7. Charles A. Advances in the basic and clinical science of migraine. Ann Neurol 2009 May; 65 (5): 491-8
8. Pietrobon D, Striessnig J. Neurobiology of migraine. Nat Rev Neurosci 2003 May; 4 (5): 386-98
9. Lambert GA, Truong L, Zagami AS. Effect of cortical spreading depression on basal and evoked traffic in the trigeminovascular sensory system. Cephalalgia 2011 Oct; 31 (14): 1439-51
10. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000 Sep 26; 55 (6): 754-62
11. Tepper SJ, Spears RC. Acute treatment of migraine. Neurol Clin 2009 May; 27 (2): 417-27
12. Lipton RB, Stewart WF, Stone AM, et al., Disability in Strategies of Care Study group. Stratified care vs step care strategies for migraine: the Disability in Strategies of Care (DISC) Study: a randomized trial. JAMA 2000 Nov 22-29; 284 (20): 2599-605
13. Tepper SJ. Acute treatment of migraine. Continuum 2006; 12 (6): 87-105
14. Edmeads J, Lainez JM, Brandes JL, et al. Potential of the Migraine Disability Assessment (MIDAS) Questionnaire as a public health initiative and in clinical practice. Neurology 2001; 56 (6 Suppl. 1): S29-34
15. Stewart WF, Lipton RB, Dowson AJ, et al. Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability. Neurology 2001; 56 (6 Suppl. 1): S20-8
16. Stewart WF, Lipton RB, Kolodner KB, et al. Validity of the Migraine Disability Assessment (MIDAS) score in comparison to a diary-based measure in a population sample of migraine sufferers. Pain 2000 Oct; 88 (1): 41-52
17. Stewart WF, Lipton RB, Whyte J, et al. An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology 1999 Sep 22; 53 (5): 988-94
18. Kosinski M, Bayliss MS, Bjorner JB, et al. A six-item shortform survey for measuring headache impact: the HIT-6. Qual Life Res 2003 Dec; 12 (8): 963-74
19. Sculpher M, Millson D, Meddis D, et al. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: the Disability in Strategies for Care (DISC) Study. Pharmacoeconomics 2002; 20 (2): 91-100
20. Berde B, Sturmer E. Introduction to the pharmacology of ergot alkaloids and related compounds as a basis of their therapeutic application. In: Berde B, Shild HO, editors. Ergot alkaloids and related compounds. New York (NY): Springer-Verlag, 1978
21. Saper JR, Silberstein S. Pharmacology of dihydroergotamine and evidence for efficacy and safety in migraine. Headache 2006 Nov; 46 Suppl. 4: S171-81
22. Goadsby PJ, Edvinsson L. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993 Jan; 33 (1): 48-56
23. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 1988 Jun; 8 (2): 83-91
24. Muller-Schweinitzer E. Venoconstrictor responses to dihydroergocristine and dihydroergotamine: evidence for the involvement of 5-HT1 like receptors. Cardiovasc Drugs Ther 1990 Dec; 4 (6): 1455-60
25. Muller-Schweinitzer E, Rosenthaler J. Dihydroergotamine: pharmacokinetics, pharmacodynamics, and mechanism of venoconstrictor action in beagle dogs. J Cardiovasc Pharmacol 1987 Jun; 9 (6): 686-93
26. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 1: triptans, dihydroergotamine, and magnesium. Headache 2012 Jan; 52 (1): 114-28
27. Moskowitz MA. Basic mechanisms in vascular headache. Neurol Clin 1990 Nov; 8 (4): 801-15
28. Masterson CG, Durham PL. DHE repression of ATPmediated sensitization of trigeminal ganglion neurons. Headache 2010 Oct; 50 (9): 1424-39
29. Nagy AJ, Gandhi S, Bhola R, et al. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology 2011 Nov 15; 77 (20): 1827-32
30. Horton BT, Peters GA, Blumenthal LS. A new product in the treatment of migraine: a preliminary report. Mayo Clin Proc 1945; 20: 241-8
31. Callaham M, Raskin N. A controlled study of dihydroergotamine in the treatment of acute migraine headache. Headache 1986 Apr; 26 (4): 168-71
32. Raskin NH. Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986 Jul; 36 (7): 995-7
33. Belgrade MJ, Ling LJ, Schleevogt MB, et al. Comparison of single-dose meperidine, butorphanol, and dihydroergotamine in the treatment of vascular headache. Neurology 1989 Apr; 39 (4): 590-2
34. Bell R, Montoya D, Shuaib A, et al. A comparative trial of three agents in the treatment of acute migraine headache. Ann Emerg Med 1990 Oct; 19 (10): 1079-82
35. Klapper JA, Stanton JS. Ketorolac versus DHE and metoclopramide in the treatment of migraine headaches. Headache 1991 Sep; 31 (8): 523-4
36. Klapper JA, Stanton JS. The emergency treatment of acute migraine headache; a comparison of intravenous dihydroergotamine, dexamethasone, and placebo. Cephalalgia 1991; 11 Suppl. 11: 159-60
37. Haugh MJ, Lavender L, Jensen A, et al. An office-based double-blind comparison of dihydroergotamine vs dihydroergotamine/metoclopramide in the treatment of acute migraine [abstract]. Headache 1992; 32: 251
38. Saadah HA. Abortive headache therapy in the office with intravenous dihydroergotamine plus prochlorperazine. Headache 1992 Mar; 32 (3): 143-6
39. Klapper JA, Stanton J. Current emergency treatment of severe migraine headaches. Headache 1993 Nov-Dec; 33 (10): 560-2
40. Scherl ER, Wilson JF. Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache 1995 May; 35 (5): 256-9
41. Winner P, Ricalde O, Le Force B, et al. A double-blind study of subcutaneous dihydroergotamine vs subcutaneous sumatriptan in the treatment of acute migraine. Arch Neurol 1996 Feb; 53 (2): 180-4
42. Carleton SC, Shesser RF, Pietrzak MP, et al. Double-blind, multicenter trial to compare the efficacy of intramuscular dihydroergotamine plus hydroxyzine versus intramuscular meperidine plus hydroxyzine for the emergency department treatment of acute migraine headache. Ann Emerg Med 1998 Aug; 32 (2): 129-38
43. Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine headache. Headache 2001 Nov-Dec; 41 (10): 976-80
44. Swidan SZ, Lake 3rd AE, Saper JR. Efficacy of intravenous diphenhydramine versus intravenous DHE-45 in the treatment of severe migraine headache. Curr Pain Headache Rep 2005 Feb; 9 (1): 65-70
45. Silberstein SD, Young WB. Safety and efficacy of ergotamine tartrate and dihydroergotamine in the treatment of migraine and status migrainosus: Working Panel of the Headache and Facial Pain Section of the American Academy of Neurology. Neurology 1995 Mar; 45 (3 Pt 1): 577-84
46. Shrewsbury SB, Cook RO, Taylor G, et al. Safety and pharmacokinetics of dihydroergotamine mesylate administered via a Novel (Tempo) inhaler. Headache 2008 Mar; 48 (3): 355-67
47. Aurora SK, Silberstein SD, Kori SH, et al. MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine. Headache 2011 Apr; 51 (4): 507-17
48. Tepper SJ, Kori SH, Goadsby PJ, et al. MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments. Mayo Clin Proc 2011 Oct; 86 (10): 948-55
49. Saxena PR, Ferrari MD. 5-HT(1)-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989 May; 10 (5): 200-4
50. Hargreaves RJ, Shepheard SL. Pathophysiology of migraine: new insights. Can J Neurol Sci 1999 Nov; 26 Suppl. 3: S12-9
51. Humphrey PP, Apperly E, Feniuk W, et al. A rational approach to identifying a fundamentally new drug for the treatment of migraine. In: Saxena PR, Wallis DI, Wouters W, et al., editors. Cardiovascular pharmacology of 5-hydroxytryptamine. Dordrecht: Kluwer Academic Publishers, 1990: 417-31
52. Humphrey PP, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 1989; 9 Suppl. 9: 23-33
53. Humphrey PP, Feniuk W, Perren MJ, et al. GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein. Br J Pharmacol 1988 Aug; 94 (4): 1123-32
54. Rapoport AM, Tepper SJ, Bigal ME, et al. The triptan formulations: how to match patients and products. CNS Drugs 2003; 17 (6): 431-47
55. Gillman PK. Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): a review. Headache 2010 Feb; 50 (2): 264-72
56. McCrory DC, Gray RN. Oral sumatriptan for acute migraine. Cochrane Database Syst Rev 2003; 3 (3): CD002915
57. Mathew NT, Landy S, Stark S, et al. Fixed-dose sumatriptan and naproxen in poor responders to triptans with a short half-life. Headache 2009 Jul; 49 (7): 971-82
58. Smith TR, Sunshine A, Stark SR, et al. Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache 2005 Sep; 45 (8): 983-91
59. Akpunonu BE, Mutgi AB, Federman DJ, et al. Subcutaneous sumatriptan for treatment of acute migraine in patients admitted to the emergency department: a multicenter study. Ann Emerg Med 1995 Apr; 25 (4): 464-9
60. Kelly AM, Ardagh M, Curry C, et al. Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine. J Accid Emerg Med 1997 Jul; 14 (4): 209-11
61. Hay E, Rodrig J, Hussain A, et al. Rizatriptan RPD for severe migraine in the emergency department: a multicenter study. J Emerg Med 2003 Oct; 25 (3): 245-9
62. Meredith JT, Wait S, Brewer KL. A prospective doubleblind study of nasal sumatriptan versus IV ketorolac in migraine. Am J Emerg Med 2003 May; 21 (3): 173-5
63. Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs sumatriptan for the emergency department treatment of migraines. Neurology 2005 Feb 8; 64 (3): 463-8
64. Friedman BW, Hochberg M, Esses D, et al. A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines. Headache 2006 Jun; 46 (6): 934-41
65. Miner JR, Smith SW, Moore J, et al. Sumatriptan for the treatment of undifferentiated primary headaches in the ED. Am J Emerg Med 2007 Jan; 25 (1): 60-4
66. Kostic MA, Gutierrez FJ, Rieg TS, et al. A prospective, randomized trial of intravenous prochlorperazine versus subcutaneous sumatriptan in acute migraine therapy in the emergency department. Ann Emerg Med 2010 Jul; 56 (1): 1-6
67. Suthisisang CC, PoolsupN, SuksomboonN, et al. Meta-analysis of the efficacy and safety of naproxen sodium in the acute treatment of migraine. Headache 2010 May; 50 (5): 808-18
68. Suthisisang C, Poolsup N, Kittikulsuth W, et al. Efficacy of low-dose ibuprofen in acute migraine treatment: systematic review and meta-analysis. Ann Pharmacother 2007 Nov; 41 (11): 1782-91
69. Jakubowski M, Levy D, Goor-Aryeh I, et al. Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors. Headache 2005 Jul-Aug; 45 (7): 850-61
70. Diener HC, Montagna P, Gacs G, et al. Efficacy and tolerability of diclofenac potassium sachets in migraine: a randomized, double-blind, cross-over study in comparison with diclofenac potassium tablets and placebo. Cephalalgia 2006 May; 26 (5): 537-47
71. Lipton RB, Grosberg B, Singer RP, et al. Efficacy and tolerability of a new powdered formulation of diclofenac potassium for oral solution for the acute treatment of migraine: results from the International Migraine Pain Assessment Clinical Trial (IMPACT). Cephalalgia 2010 Nov; 30 (11): 1336-45
72. Marmura MJ. Use of dopamine antagonists in treatment of migraine. Curr Treat Options Neurol 2012 Feb; 14 (1): 27-35
73. Peroutka SJ, Wilhoit T, Jones K. Clinical susceptibility to migraine with aura is modified by dopamine D2 receptor (DRD2) NcoI alleles. Neurology 1997 Jul; 49 (1): 201-6
74. Fernandez F, Lea RA, Colson NJ, et al. Association between a 19 bp deletion polymorphism at the dopamine beta-hydroxylase (DBH) locus and migraine with aura. J Neurol Sci 2006 Dec 21; 251 (1-2): 118-23
75. Loder E. Migraine in pregnancy. Semin Neurol 2007 Nov; 27 (5): 425-33
76. Colman I, Brown MD, Innes GD, et al. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ 2004 Dec 11; 329 (7479): 1369-73
77. Bigal ME, Bordini CA, Speciali JG. Intravenous chlorpromazine in the emergency department treatment of migraines: a randomized controlled trial. J Emerg Med 2002 Aug; 23 (2): 141-8
78. Shrestha M, Singh R, Moreden J, et al. Ketorolac vs chlorpromazine in the treatment of acute migraine without aura: a prospective, randomized, double-blind trial. Arch Intern Med 1996 Aug 12-26; 156 (15): 1725-8
79. Jones J, Sklar D, Dougherty J, et al. Randomized doubleblind trial of intravenous prochlorperazine for the treatment of acute headache. JAMA 1989 Feb 24; 261 (8): 1174-6
80. Seim MB, March JA, Dunn KA. Intravenous ketorolac vs intravenous prochlorperazine for the treatment of migraine headaches. Acad Emerg Med 1998 Jun; 5 (6): 573-6
81. Ginder S, Oatman B, Pollack M. A prospective study of i.v. magnesium and i.v. prochlorperazine in the treatment of headaches. J Emerg Med 2000 Apr; 18 (3): 311-5
82. Derry S, Moore RA, McQuay HJ. Paracetamol (acetaminophen) with or without an antiemetic for acute migraine headaches in adults. Cochrane Database Syst Rev 2010 Nov 10; 11 (11): CD008040
83. Tfelt-Hansen P, Olesen J. Paracetamol (acetaminophen) versus acetylsalicylic acid in migraine. Eur Neurol 1980; 19 (3): 163-5
84. Lipton RB, Stewart WF, Ryan Jr RE, et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol 1998 Feb; 55 (2): 210-7
85. Goldstein J, Hoffman HD, Armellino JJ, et al. Treatment of severe, disabling migraine attacks in an over-the-counter population of migraine sufferers: results from three randomized, placebo-controlled studies of the combination of acetaminophen, aspirin, and caffeine. Cephalalgia 1999 Sep; 19 (7): 684-91
86. Diener HC, Pfaffenrath V, Pageler L, et al. The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study. Cephalalgia 2005 Oct; 25 (10): 776-87
87. Freitag FG, Cady R, DiSerio F, et al. Comparative study of a combination of isometheptene mucate, dichloralphenazone with acetaminophen and sumatriptan succinate in the treatment of migraine. Headache 2001 Apr; 41 (4): 391-8
88. Moskowitz MA, Cutrer FM. Sumatriptan: a receptortargeted treatment for migraine. Annu Rev Med 1993; 44: 145-54
89. May A, Shepheard SL, Knorr M, et al. Retinal plasma extravasation in animals but not in humans: implications for the pathophysiology ofmigraine. Brain 1998 Jul; 121 (Pt 7): 1231-7
90. Friedman BW, Greenwald P, Bania TC, et al. Randomized trial of IV dexamethasone for acute migraine in the emergency department. Neurology 2007 Nov 27; 69 (22): 2038-44
91. Donaldson D, Sundermann R, Jackson R, et al. Intravenous dexamethasone vs placebo as adjunctive therapy to reduce the recurrence rate of acute migraine headaches: a multicenter, double-blinded, placebo-controlled randomized clinical trial. Am J Emerg Med 2008 Feb; 26 (2): 124-30
92. Rowe BH, Colman I, Edmonds ML, et al. Randomized controlled trial of intravenous dexamethasone to prevent relapse in acute migraine headache. Headache 2008 Mar; 48 (3): 333-40
93. Fiesseler FW, Shih R, Szucs P, et al. Steroids for migraine headaches: a randomized double-blind, two-armed, placebo-controlled trial. J Emerg Med 2011 Apr; 40 (4): 463-8
94. Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 3: opioids, NSAIDs, steroids, and post-discharge medications. Headache 2012 Mar; 52 (3): 467-82
95. Bigal ME, Lipton RB. Excessive acute migraine medication use and migraine progression. Neurology 2008 Nov 25; 71 (22): 1821-8
96. Members of the task force:, Evers S, Afra J, Frese A, et al. EFNS guideline on the drug treatment of migraine-report of an EFNS task force. Eur J Neurol 2006 Jun; 13 (6): 560-72